Honda turned the North American debut of its new Fit into a fanciful drive to nowhere. The background moved, but for the most part, the car didn't -- with a wonderful result.
"We wanted to unveil the all-new 2015 Honda Fit in a way that tells the story of the car: youthful, innovative, exciting and fun-to-drive with incredible packaging," says Honda spokeswoman Robyn Eagles.
The Fit is the smallest car in Honda's line, with the new Fit being even an inch shorter than the last. So the goal was to showcase the flexibility that takes advantage of the fact that it has more space inside than the current version.
5 Best Semiconductor Stocks To Watch For 2015: Central European Media Enterprises Ltd.(CETV)
Central European Media Enterprises Ltd., a media and entertainment company, operates broadcast, content, and new media businesses in central and eastern Europe. The company operates in three segments: Broadcast, Media Pro Entertainment, and New Media. The Broadcast segment operates 30 television channels reaching an aggregate of approximately 49 million people primarily in 6 countries. It operates television channels, including BTV, BTV CINEMA, BTV COMEDY, RING.BG, BTV ACTION, and BTV LADY, a female-oriented cable channel in Bulgaria; NOVA TV, DOMA, and NOVA WORLD in Croatia; TV NOVA, NOVA CINEMA, NOVA SPORT, and MTV CZECH in the Czech Republic; PRO TV, PRO TV INTERNATIONAL, ACASA, PRO CINEMA, MTV ROMANIA, PRO TV CHISINAU, and SPORT.RO in Romania; TV MARK�A and DOMA in the Slovak Republic; POP TV, KANAL A, and POP BRIO in Slovenia, as well as various radio channels in Bulgaria. The Media Pro Entertainment segment develops, produces, and distributes content for its own te levision channels, as well as to third parties through the theatrical and home video operations; sells DVD and Blu Ray discs to wholesale and retail clients; and distributes theatrical, home entertainment, digital, and television film rights. It also owns and operates 16 cinema screens in Romania. The New Media segment offers television content; and operates various news portals, niche Websites, and television-related Websites. Central European Media Enterprises Ltd. was founded in 1994 and is based in Hamilton, Bermuda.
Advisors' Opinion:- [By Eric Volkman]
A new common stock issue from Central European Media Enterprises (NASDAQ: CETV ) now has a price tag. The broadcasting group is floating nearly 54.5 million shares of its class A common stock in an underwritten public offering, for which it will charge $2.75 per share. The company's underwriters have been granted a 30-day purchase option to buy up to an additional 5.4 million-plus shares.
- [By Monica Gerson]
Central European Media Enterprises (NASDAQ: CETV) shares dropped 25.53% to $4.55 in pre-market trading after the company posted an operating loss in the third quarter and lowered its 2013 outlook.
- [By Roberto Pedone]
Central European Media Enterprises (CETV) is a media and entertainment company that operates broadcast, content and new media businesses in central and Eastern Europe. This stock closed up 5.1% to $3.68 in Thursday's trading session.
Thursday's Range: $3.50-$3.80
52-Week Range: $2.60-$7.92
Thursday's Volume: 365,000
Three-Month Average Volume: 741,458From a technical perspective, CETV bounced sharply higher here right off its 50-day moving average of $3.42 with lighter-than-average volume. This move is quickly pushing shares of CETV within range of triggering a major breakout trade. That trade will hit if CETV manages to take out some near-term overhead resistance levels at $3.79 to $3.89 with high volume.
Traders should now look for long-biased trades in CETV as long as it's trending above its 50-day at $3.42 or above more near-term support at $3.25 and then once it sustains a move or close above those breakout levels with volume that hits near or above 741,458 shares. If that breakout hits soon, then CETV will set up to re-test or possibly take out its next major overhead resistance levels at $4.45 to $4.68. Any high-volume move above those levels will then put its next major overhead resistance levels at $5 to $5.25 into range for shares of CETV.
Top 10 International Companies To Buy For 2014: International Star Inc (ILST)
International Star, Inc., incorporated October 28, 1993, is primarily engaged in the acquisition and exploration of precious and base metals mineral properties. The Company�� properties are located in Arizona. As of December 31, 2010, the Company held 43 claims in the adjacent northern Black Mountains in Mohave County, and its current exploration activities are focused on these claims and surrounding areas of interest. As of September 1, 2010, the Company no longer held any mining claims in its former Wikieup property. The Wikieup Property formerly consisted of 42 lode claims comprising approximately 840 acres in the Hualapai Mountain Range at Wikieup, Arizona.
Mohave County, Arizona Property
The mineral property consists of approximately 1.4 square miles of land located in the northern Black Mountains in Mohave County, Arizona, approximately 56 miles from Las Vegas, Nevada, and 22 miles south of the Hoover Dam on United States Highway 93 (the Black Mountains Property). The property is easily accessed by partially paved entry off Highway 93 and has availability to electricity and water. Its Black Mountains Property consists of approximately 43 lode claims. Its claim holdings in this area began with placer claims in the adjacent Detrital Wash area. The Black Mountains Property is underlain by three basic rock units or packages of rocks. The oldest rock unit consists of Precambrian schist and gneissic rocks, which are the reconstituted (metamorphic) equivalents of former shale, siltstone, and volcanic rocks.
The property exhibits features of a metamorphic core complex. These features include the somewhat arch-like, cross-sectional (east-west) profile of this area of the Black Mountains, detached cover rocks, a preponderance of shallow-dipping penetrative structures (foliations) in the plutonic/metamorphic basement, and the composition of the plutonic rocks. The Company�� exploration efforts are primarily focused on the establishment of gold reserves with a seco! ndary focus on copper and other minerals. During the year ended December 1, 2010, the Company conducted drilling and additional sampling and mapping work on certain areas of its Black Mountains Property showing high mineralization results. During 2010, it allowed approximately 60 of its previously filed claims to expire and added approximately 25 claims covering nearby areas.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks International Star Inc (OTCMKTS: ILST) and Mining Minerals of Mexico Corp (OTCMKTS: WIIM) sank 13.33% and 24.9%, respectively, today, with at least one of these small cap stocks being the subject of paid promotions or investor relations type of activities while the other has had no news since last summer. So should you dig into these small cap mining stocks which just dug a hole for investors and traders alike? Here is a closer look to help you decide:
Top 10 International Companies To Buy For 2014: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
Sarepta Therapeutics (NASDAQ: SRPT ) announced yesterday after the market closed that the U.S. Food and Drug Administration requested additional information before it could make a decision on acceptability of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Sarepta shares were down more than 12% in early trading.
- [By Ernie Tremblay, Biosciences Specialist, Money Morning | January 17, 2014 · ]
When I'm setting out in search of a lucrative bioscience stock, here are some qualities I find really attractive:
Market cap. $250M-$2.5B. This is the sweet spot for growth. Less than $250M can mean low volume trading, which can be a problem if you need to sell. More than $2.5B makes a company less responsive to catalysts. Single product pipeline. These companies can yield high returns because they carry high risk. If their drug succeeds, their investors can get rich rapidly. A failure, however, can mean doom, so you need to know what you're doing in evaluating the drug's potential to be effective, safe, convincing to the FDA, and marketable. Some of my recommendations, of course, are for companies that have richer pipelines. They yield less return, but they're safer bets for a balanced portfolio. An upcoming catalyst. A catalyst, such as an AdCom, FDA approval date (called a PDUFA), or even results from a clinical trial, can make you a whole lot richer overnight. Last year, Sarepta Therapeutics (Nasdaq: SRPT) tripled its stock price overnight when the company announced positive results for a study of its Duchenne muscular dystrophy drug. Orphan drug status. As I explained above, these drug candidates have real advantages over traditional "blockbuster" entries. An extreme need. Everyone born with HoFH would eventually die from it, and before Aegerion's Juxtapid (lomitapide), no effective treatment existed. Patients were longing for it. Little or no competition. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS), in partnership with Genzyme Pharmaceuticals, was developing a drug, mimoperson, to compete with Juxtapid, but it was inferior in several ways (injectable rather than oral, more severe side effects). It also passed its AdCom, but barely, garnering a vote of 9 to 6. Juxtapid had a nearly clear field to play in. The Profits AheadNext, of course, comes the tricky part. You've got to be able to read studies on exper
- [By Jayson Derrick]
The FDA's Center for Drug Evaluation and Research stated that the agency is exploring potential pathways to approve new drugs that could be used to treat Duchenne muscular dystrophy. Specifically, Sarepta Therapeutics' (NASDAQ: SRPT) eteplirsen was mentioned as potentially being placed in an accelerated approval program. Shares gained 12.79 percent, closing at $22.93.
- [By Roberto Pedone]
One name that's starting to trend within range of triggering a big breakout trade is Sarepta Therapeutics (SRPT), which discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen. This stock has been uptrending strong so far in 2013, with shares up 45%.
If you take a look at the chart for Sarepta Therapeutics, you'll notice that this stock has been uptrending strong over the last month, with shares moving higher from its low of $29.71 to its intraday high of $38.16 a share. During that uptrend, shares of SRPT have been consistently making higher lows and higher highs, which is bullish technical price action. Shares of SRPT have now started to spike back above its 50-day moving average of $37.50, and that move is quickly pushing SRPT within range of triggering a big breakout trade.
Traders should now look for long-biased trades in SRPT if it manages to break out above its 50-day at $37.50 a share and then once it clears some key near-term overhead resistance at $39.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.65 million shares. If that breakout hits soon, then SRPT will set up to re-test or possibly take out its next major overhead resistance levels at $46 to $47 a share.
Traders can look to buy SRPT off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $35.31 to $35 a share. One can also buy SRPT off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 International Companies To Buy For 2014: Parker Drilling Co (PAD)
Parker Drilling Company (Parker), incorporated on August 4, 1970, is a provider of contract drilling and drilling-related services. The Company operates in six segments: Rental Tools, U.S. Barge Drilling, U.S. Drilling, International Drilling, Technical Services and Construction Contract. During year ended December 31, 2012, the Company operated in 12 countries. The Company has operated in over 50 foreign countries and the United States. In April 2013, the Company announced the acquisition of International Tubular Services Limited and certain affiliates (ITS), subsidiaries of ITS Tubular Services (Holdings) Limited.
Rental Tools Business
The Company provide premium rental tools for land and offshore oil and natural gas drilling and provide equipment used for drilling, workover and production applications, such as drill pipe, heavy-weight drill pipe, tubing, high-torque connections, blow-out preventers (BOPs) and drill collars. The Company also hold an inventory of rental tools and provide service to its customers from locations in Louisiana, Texas, Wyoming, North Dakota and West Virginia.
U.S. Barge Drilling Business
The Company�� U.S. Gulf of Mexico barge rig fleet is marketed barge fleet in the GOM region, with rigs ranging from 1,000 to 3,000 horsepower with drilling depth capabilities ranging from 13,000 to over 30,000 feet. The Company�� rigs drill for oil, natural gas, and a combination of oil and natural gas in the shallow waters in and along the inland waterways and coasts of Louisiana, Alabama and Texas.
U.S. Drilling Business
The Company�� U.S. Drilling segment primarily consists of two new-design Arctic Alaska Drilling Unit (AADU) land rigs. In addition to the two AADU rigs, the Company has one land rig at its facility in New Iberia, Louisiana.
International Drilling Business
The Company�� international drilling business includes operations related to Parker-owned and operated ri! gs as well as customer-owned rigs. In addition, it perform drilling-related activities for operators who own their drilling rigs and who choose to utilize its drilling experience and technical expertise to perform services on a contracted basis, including Operations and Maintenance (O&M) work, and other project management services (such as labor, maintenance, and logistics).
Technical Services Business
The Company�� technical services business primarily includes its engagement in concept development, pre-FEED (Front End Engineering Design), Front End Engineering Design (FEED) and Engineering, Procurement, Construction and Installation (EPCI) projects. During the EPCI phase, it focuses primarily on the drilling systems engineering, procurement, commissioning and installation and provide customer support during construction. As of December 31, 2012, it provides these services on the Berkut platform project for Exxon Neftegas Limited (ENL).
Construction Contract Business
The Company�� construction contract segment includes only the BP-owned Liberty extended-reach drilling rig construction project. Under the consulting services agreement, it assisted BP in a review of the rig�� design, the creation of a new statement of requirements for the rig, and the transition of documentation and materials to BP.
Advisors' Opinion:- [By James Oberweis]
Among our latest small-cap recommendations is a medical device company focused on developing minimally invasive treatment solutions for vascular disease, including peripheral artery disease (PAD) and coronary artery disease (CAD), explains Jim Oberweis, Editor of The Oberweis Report.
Top 10 International Companies To Buy For 2014: PetroChina Company Limited(PTR)
PetroChina Company Limited produces and distributes oil and gas in the People?s Republic of China. It operates in four segments: Exploration and Production, Refining and Chemicals, Marketing, and Natural Gas and Pipeline. The Exploration and Production segment explores, develops, produces, and markets crude oil and natural gas, oilsands, and coalbed methane. As of December 31, 2010, it had 11,278 million barrels of proved reserves of crude oil; and 65,503 billion cubic feet of proved reserves of natural gas. The Refining and Chemicals segment engages in the refining of crude oil and petroleum products; and production and marketing of petrochemical products, derivative petrochemical products, and other chemical products. This segment?s product line comprises processed crude oil, gasoline, kerosene, diesel, ethylene, synthetic resins, synthetic fiber materials, polymers, synthetic rubber, and urea. The Marketing segment involves in the marketing of refined products and tradi ng businesses. It operated 17,996 service stations. The Natural Gas and Pipeline segment engages in the transmission of natural gas, crude oil, and refined products; and the sale of natural gas. It had a total length of 56,840 kilometers (km) of oil and gas pipelines, including 32,801 km of natural gas pipelines, 14,782 km of crude oil pipelines, and 9,257 km of refined product pipelines. The company was founded in 1988 and is headquartered in Beijing, the People?s Republic of China. PetroChina Company Limited is a subsidiary of China National Petroleum Corporation.
Advisors' Opinion:- [By vaninaegea]
I find the analysis and comparison between companies with base in different geographies an entertaining exercise that offers a singular perspective upon future prospects. In other words, business activities are approached from diverse angles according to social, political, and economical background. Hence, Petroleo Brasileiro (PBR) and PetroChina (PTR) do compete in the same segments, but results are separated by a gamut of particularities.
- [By Jim Jubak]
The auction news isn't good for investors in Brazil's Petrobras (PBR), but it could well be a boon for China and Chinese oil companies such as PetroChina (PTR) and CNOOC (CEO).
- [By GuruFocus]
In the past you have made a few investments in China, Petrol China (PTR), BYD, given growing importance, what advice would you give to Chinese leadership?
- [By MARKETWATCH]
HONG KONG (MarketWatch) -- Hong Kong stocks opened higher on Tuesday, as global investors look ahead to U.S. Federal Reserve Chairwoman Janet Yellen's first public remarks later in the day. The Hang Seng Index (HK:HSI) rose 0.7% to 21,722.66. Asia's largest oil and gas company -- PetroChina Co. Ltd (HK:857) (PTR) -- climbed 2%, after the company said it has found a large natural-gas reserve in China's southwestern Sichuan basin, with 308 cubic meters of technically recoverable gas. Cnooc Ltd. (HK:883) (CEO) , China's largest offshore oil and gas producer, jumped 3.3%, while top refiner China Petroleum & Chemical Corp. (HK:386) (SNP) also added 1.6%. Oilfield-equipment shares also benefited from the rally, as China Oilfield Services Ltd. (HK:2883) (CHOLF) gained 1.7%. Huadian Fuxin Energy Corp. Ltd. (HK:816) , the renewable-energy unit of Chinese state-owned power giant China Huadian Corp., jumped 3.2%, after the company said last week it had raised 1.18 billion Hong Kong dollars (about $152 million) through a sale of shares to institutional investors. Waste-management and energy company China Everbright International Ltd. (HK:257) (CHFFF) advanced 2.4%, and China Datang Renewable Power Co. Ltd. (HK:1798) tacked on
Top 10 International Companies To Buy For 2014: iShares Global Tech ETF (IXN)
iShares S&P Global Technology Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor�� Global Information Technology Sector Index (the Index). The Index is a subset of the Standard & Poor�� Global 1200 Index, and measures the performance of companies that Standard & Poor�� deems to be part of the information technology sector. Component companies include those involved in the development and production of technology products, including computer hardware and software, telecommunications equipment, microcomputer components, integrated computer circuits and office equipment utilizing technology.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Russ Koesterich]
The list above is based on my team's analysis of whether sector valuations appropriately price in each sector's expected earnings growth, profitability and risk. Based on these factors, I have a preference for the energy and informational technology sectors, accessible through the iShares S&P Global Energy Sector Fund (IXC) and the iShares S&P Global Technology Sector Fund (IXN). And as I write in my new Investment Directions commentary piece, if it turns out that we do see more investors rotating out of defensives and into more attractively priced cyclicals, these two sectors are poised to especially benefit.
Top 10 International Companies To Buy For 2014: PGT Inc.(PGTI)
PGT, Inc. engages in the manufacture and supply of residential impact-resistant windows and doors. The company offers impact-resistant products, including heavy-duty aluminum or vinyl frames with laminated glass to provide protection from hurricane-force winds and wind-borne debris. It also provides a range of non-impact-resistant aluminum and vinyl frame windows and doors; Architectural Systems line of products, which offer protection from hurricane-force winds and wind-borne debris for mid-and high-rise buildings; and non-glass vertical and horizontal sliding panels for porch enclosures, such as vinyl-glazed and aluminum-framed products used for enclosing screened-in porches that provide protection from inclement weather. The company markets its products under the WinGuard, PremierVue, PGT Architectural Systems, Eze-Breeze, and SpectraGuard brand names. PGT, Inc. offers its products to residential new construction, and home repair and remodeling end markets through windo w distributors, building supply distributors, window replacement dealers, and enclosure contractors. It operates in the southeastern United States, the Gulf Coast, Coastal mid-Atlantic, the Caribbean, Central America, and Canada. The company was formerly known as JLL Window Holdings, Inc. and changed its name to PGT, Inc. in January 2004. PGT, Inc. was founded in 1980 and is based in North Venice, Florida.
Advisors' Opinion:- [By Seth Jayson]
There's no foolproof way to know the future for PGT (Nasdaq: PGTI ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.
No comments:
Post a Comment